Figure 1From: A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting Decision analysis tree: patient outcomes during a period from surgery to 3 months postoperatively. Back to article page